1 glycoprotein gp120 can dissociate from the viral envelope either spontaneously or after binding of HIV-1 to the CD4 molecule. As a consequence, gp120 can circulate in the patient's serum and attach to the surface of uninfected CD4+ T cells. Complement activation by cell-bound HIV-1 glycoprotein gplZ0 with subsequent opsoniration may represent a mechanism for the elimination of uninfected CD4' cells by the reticuloendothelial system, thereby enhancing the progression of HIV disease. In the current study, the complement proteins C4, C3, C5, C9, and properdin were found to bind to a synthetic peptide covering positions 233-251 of the gp120sRu sequence on incubation with normal human serum. Complement activation by the peptide was comparable with that induced by aggregated IgG, complete rgpl20, E SHOWED RECENTLY that recombinant glycoprotein 120 (rgpl20) of human immunodeficiency virus type-l (HIV-l), either attached to microtiter plates or bound to CD4+ T cells of healthy individuals, activates the human complement system in the absence of anti-gpl20 antibodies.'. 2 Other investigators showed that HIV-1 can activate the complement system in human and animal sera in the absence of anti-HIV-l Certain animal sera can lyse HIV-l and W-1-infected However, activation of the human complement system appears to be insufficient for inducing lysis of the human retroviruses human T-cell lymphotrophic virus type-l and HIValthough it is sufficient for the lysis of retroviruses of avian, feline, murine, and simian origin in an antibody-independent manner.14 We showed that lysis of HN-1-infected cells by rabbit sera is caused by the presence of naturally occurring IgM-anti-gpl20 antibodies, which were not found in human sera.2 Moreover, the inefficiency of normal human serum (NHS) in lysing HIV-1 appears to be related to the appearance of complement-inhibitov molecules on the virions that prevent the formation of the membrane-attack complex of ~omplement.'~.'~ Besides not being protective, activation of the human complement system was reported to even enhance HIV-1 infection of cells that bear complement receptors (CRs) on their surface, including CD4-cell^.'"^'
To establish the precise role of complement in the pathogenesis of acquired immunodeficiency syndrome (AIDS), it is necessary to determine the complement-activating sites of HIV-1 proteins. Soluble gp41 and synthetic peptides of gp41 were reported to bind the Clq subunit of the first complement component in the absence of antibodies.22 However, no Clq binding or complement activation by rgpl20 or a gp120 peptide from the immunodominant v3-100~ epitope was observed in previous s t u d i e~. "~~~ We were able to show that, besides gp41, rgpl20 of HIV-1 is also capable of activating the human complement system in the absence of anti-gp120 antibodies.'.2 Independently, other investigators reported similar Complement activation by cell-bound HIV-l glycoprotein gp120 with subsequent opsonization was suggested to represent a possible mechanism for the &mina- and the previously described complement-activating gp41-peptide 609-623. Activation occurred via the classical pathway and was abrogated in the presence of EDTA, Mg2+/ EGTA, or (%deficient human serum. Peptides partly overlapping the sequence 233-251 activated complement to a lesser extent. The complement-activating capacity of the gp120 sequence 233-251 was not restricted to the HIV-lmU isolate, because a peptide from the corresponding sequence of the HIV-~MN strain was also capable of activating complement. An additional strong complement-activating site was identified in the gp120 sequence 321-360 of the HIV-lyN strain.
These data indicate that distinct sites in gp120 are able to activate human serum complement via the classical pathway in the absence of anti-gpl20 and independent of glycosylation.
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tion of uninfected CD4' cells in HIV+ patients. HIV-l glycoprotein gp120 dissociates from the viral envelope either spontaneously or after binding of HIV-1 to the CD4 mole~u l e .~~" '
As a consequence, gp120 can circulate in the patient's serum and attach to the surface of uninfected CD4+ T cells.3z Using peptides from the gp120 sequence of two different HIV-1 isolates, BRU and MN, in the current study, we attempted to determine the specific sites of gp120 that are involved in the direct activation of human complement in the absence of anti-gpl20 antibodies.
MATERIALS AND METHODS

Reagents and buflers.
Normal human sera were obtained from 12 anti-HIV-healthy individuals. Heat-aggregated Ig was prepared by heating of human IgG for 30 minutes at 63°C. Veronal-buffered saline (VBS) containing 5 mmoVL sodium barbital (pH 7.4), 0.15 mmoVL CaC12, 1 mmoVL MgClz and 150 mmol/L NaCl was prepared as described by Rapp and Bor~os.'~ CCdeficient human serum was purchased from Behring (Marburg, Germany). C4 was purified to homogeneity by sequential ion-exchange chromatography on QAE Sephadex A50, DEAE Sephacel, and Mono Q P L C columns (Pharmacia, Freiburg, Germany). Clq was purchased from Sigma (Miinchen, Germany). rgpl20, 18 different gp120 peptides, and a gp41 peptide covering a previously described complement-activating sequence (Number 26) were obtained from Societk Nationale des Poudres et Explosifs (Frankfurt, Germany). rgpl20 was derived from MT] ). In addition, peptide 8 was synthesized by Dr R. Pipcorn (German Cancer Research Center, Heidelberg, Germany) using the Fmoc polyamide active ester chemistry method in an AB1 433 peptide synthesizer (Applied Biosystems, Weiterstadt, Germany). In complement-activation assays, the two peptide-8 preparations showed an identical behavior. Table 1 lists the amino acid sequences of the peptides. All peptide sequences are represented in the gp160 sequence of HIV-lBRU isolate. An additional peptide set containing 47 overlapping peptides from the gp120 sequence of the H I V -1~ strain was obtained from the National Institutes of Health AIDS Research and Reference Reagent Program (Table 2) .
Complement ucrivurion by gp120 peptides. The 96-we11 MaxiSorp microtiter plates (Nunc, Roskilde, Denmark) were coated for 16 hours at 4°C with 500 ng/well of the peptides. Uncoated sites were blocked for 1 hour at 22°C with phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA). The wells were incubated for 20 minutes at 37°C with NHS containing 20% (voV vol) VBS or with 100 mmollL EDTA or 50 mmol/L EGTA/25 mmol/L Mgz+, and the reaction was stopped by the addition of icecold EDTA stock solution (final concentration, 20 mmow). In one experiment, the wells were incubated with C4-deficient human serum or with CCdeficient human serum that was reconstituted with human C4 (200 pg/ml). Surface-bound complement proteins were detected by incubating the plates for 1 hour at 22°C with rabbit antibodies SUSAL ET AL to C4, C3d, and C5 (Dakopatts, Copenhagen, Denmark); and C9 and C5b-9 (Behring) or with goat antibodies to properdin (Baxter, Unterschleisheim, Germany). Peroxidase-conjugated F(ab'), fragments of goat-antirabbit IgG or rabbit-antigoat IgG were used as second antibodies (Dianova, Hamburg, Germany). In the positive control, the plates were coated with 500 ng/well of aggregated human IgG or 100 @well of rgpl20 (optimal concentration). BSA-coated wells (500 ng/well) served as negative control. PBS containing 0. l % Tween and 10 mmoVL EDTA was used as washing buffer, and citrate buffer (pH 4.3) containing 3.65 mmol/L 2,2'-azino-di-(3- For personal use only. on September 24, 2017. by guest www.bloodjournal.org From ethylbenzthiazoline sulfonate) (Sigma) and 0.05% H202 was used as substrate. Optical density was measured at 405 nm using a 340 Automated Transport Temperature Control Microplate Reader (SLT, Crailsheim, Germany). To ascertain that the microtiter plates were coated with equal amounts of the different peptides, five randomly chosen BRU-peptides (no. 1, 4, 6 , 14, and 25) along with peptide 8 were biotinylated by incubating 500 pg peptide for 16 hours at 4°C with 150 pg d-biotinyl-eamidocaproic acid n-hydroxysuccinimide ester (Boehringer Mannheim, Mannheim, Germany). Unbound biotin was eliminated by gel-filtration chromatography using Sephadex G10 (Pharmacia). Thereafter, biotinylated peptides were isolated using a Superdex PeptideMR column (Pharmacia). Binding efficiency of all peptides to microtiter plates, as measured by direct and indirect binding studies, was comparable with a less than 15% variation. Biotinylated peptides showed the same complement-activation behavior as unbiotinylated peptides.
After the incubation of serum in peptide-coated plates, supematants were removed and tested by enzyme-linked immunosorbent assay (ELISA) for the complement-activation products C3a (Progen, Heidelberg, Germany) and SC5b-9.-Clq-binding to gp120 peptides. Purified Clq (2.5 pglwell; Sigma) was incubated for 2 hours at 22°C with peptide-coated plates in the presence of 5 mmoliL CaCI2. The reaction was detected with rabbit antibodies to Clq (Dakopatts) and peroxidase-conjugated F(ab')z fragments of goat-antirabbit IgG (Dianova). PBST~een(O.O5%)-CaC1~(5rnmoVL) was used as washing buffer.
Detection of naturally occurring antibodies against rgpI20 or peptide 8 in human sera. Peripheral blood mononuclear cells of healthy volunteers were isolated by Ficoll-Hypaque density gradient centrifugation. Fifty microliters of phycoerythrin-conjugated antiLeu12 (reactive with B cells), anti-Leu2a (CD8+ T cells), and fluorescein isothiocyanate (FITC)-conjugated anti-Leu1 1 (natural killer cells) monoclonal antibodies (Becton Dickinson, Mountain View, CA) were added to 5 X IO7 mononuclear cells and incubated for 30 minutes at 4°C. After washing with PBS containing 1% BSA, CD4+ T cells were negatively selected using a FACStar Plus Cell Sorting System (Becton Dickinson). Isolated cells were greater than 90% CD4' T cells as assessed by flow-cytometric analysis. Human sera obtained from 12 healthy individuals were tested for naturally occurring antibodies against rgpl20-coated or uncoated human CD4+ T cells using FITC-conjugated goat-antihuman Ig antibodies (Medac, Hamburg, Germany) that recognize human IgG, IgM, and IgA. rgpl20-coating of CD4' T cells was confirmed by an FITC-conjugated sheep-anti-gpl20 antibody (Biochrom, Berlin, Germany) that recognizes a sequence in the COOH-terminal part of gp120 (amino acids 497 to 5 1 1). In addition, the human sera were tested for naturally occurring antibodies to BRU-peptide 8 by ELISA by incubating serial dilutions 1 1 1 1 1 1 1 1 a a a~a z l a a~a a a a a a a a a a 4 8 occurred in each of the 12 human sera tested and was as strong as that induced by aggregated IgG and complete rgpl20 and was even stronger than that induced by a gp41-peptide from the previously described complement-activating gp41-sequence 609-623.** Peptide 9, which covers the positions 236-255 (KTFNGTGPCTNVSTVQCTHG) of gp120 and, thus, overlaps with most of the sequence of peptide 8, also activated complement but to a lesser extent (Fig 1A) . Comple and, thus, covers the CD4-binding region of gp120, and an additional peptide, which was derived from the gp120 sequence 355-383, also activated complement; however, they activated complement less effectively than did peptide 8. Complement activation by peptides 13, 14, and 15, which cover the immunodominant v3-loop epitope of the BRU isolate, was weak.
Deposition of C3 was reduced to background levels when the complement-activating peptides were incubated with serum in the presence of 20 mmol EDTA, which binds Mg2+ and Ca2', thereby blocking both the classical and alternative pathways of complement activation.
Therefore, it was concluded that C3 deposition on peptide-coated plates was not caused by unspecific binding of complement proteins or a direct interaction between complement proteins and certain peptides but resulted from the activation of the complement cascade. Naturally occurring antibodies in human sera against peptide 8, which theoretically could have been responsible for complement activation, were excluded using ELISA assays.
Complement-activating capacity of the gp120 sequence 233-251 is not restricted to one isolate. Computer analyses showed that the complement-activating gp120 sequence 233-251 is 100% conserved in the HIV-1 isolates BRU, HXB2, LAI, and NL43, is 94% conserved in the SF2 isolate, and is greater than 80% conserved in 31 additional isolates. To determine whether the complement-activating capacity of this sequence is restricted to the HIV-1 isolates BRU, HXB2, LAI, and NL43, we chose a peptide from the MN isolate of HIV-1. The MN peptide covers the positions 231-250 (LKCNDKKFSGKGSCKNVSTV) of the gp12oMN sequence and, thus, overlaps with most of the sequence of peptide 8. Although being only 63% identical with the sequence of peptide 8, the MN peptide 22 activated complement as effectively as peptide 8, showing that the complement-activating capacity of this gp120 sequence is not restricted to one isolate (Fig 1B) . Furthermore, using a peptide set consisting of was-significantly reduced ( P < ,005).
47 overlapping peptides of the HIV-lMN strain (Table 2) , we were able to identify an additional complement-activation site within the gp120 sequence 321-360 that was covered by the peptides 31-33 ( Fig 1B) .
Complement activation by the gp120 sequence 233-251 occurs via the classical pathway. Incubation of human sera obtained from healthy individuals with immobilized peptide 8 from the HIV-lBR" isolate resulted in the binding of C4, C3, C5, C9, and properdin to the surface-bound peptide (indicating that activation of the complement cascade was extending beyond C3), resulted in the initiation of the terminal sequence, and involved the alternative pathway as amplification loop (Fig 2) . Only small amounts of C5b-9 were deposited on peptide-coated plates, which is in agreement with the previous observation that complement activation by HIV-1 is not sufficient for inducing lysis of HIV-l Activation of complement occurred primarily via the classical pathway and was abrogated in the presence of 10 mmol EGTN5 mmol MgC12, whereby the Ca2+-dependent C l activation (classical pathway) but not the Ca2+-independent alternative pathway activation is blocked (Fig 2) . In another experiment, addition of human serum that was deficient of the classical pathway component C4 resulted in significantly reduced C3 binding to peptide 8-coated wells, thus further supporting the role of the classical pathway in gpl20-induced complement activation. Complement activation could be reconstituted with the addition of purified C4 to the C4-deficient serum (data not shown).
To confirm that complement was activated by peptide 8 of the gp120 sequence of HIV-lBRU isolate, supernatants were tested for the presence of the fluid-phase activation products C3a and SC5b-9. High concentrations of C3a and SC5b-9 were detectable, supporting the notion that the deposition of complement fragments on peptide-coated plates was not merely caused by unspecific binding of complement proteins but by the activation of the complement cascade (Fig 3) .
Binding of puriJed C l q to gp120 peptides. As shown in Table 3 , purified Clq bound only weakly to the noncomplement-activating peptides 3 from the gp12oBRu sequence and 13 from the gp12oMN sequence. Clq-binding was observed to the complement-activating peptides 8, 9, 17, and 20 from HIV-lBRU isolate. The sequence includes three potential Nglycosylation sites at positions 235, 239, and 246, and, because of the two cysteins at positions 233 and 244, it is capable of forming a loop.
DISCUSSION
HIV-1 as well as HIV-1 -infected lymphocytes are able to activate complement in the absence of anti-HIV-1 antibodies. It was shown previously that HIV-1 glycoprotein gp41 interacts directly with Clq and that specific sites in the gp41 molecule activate human complement.22 The present study is an extension of our recent report in which we showed that glycosylated rgpl20 preparations derived from two different HIV-1 strains, IIIB and SF2, are able to activate the gp120BRu sequence and 22,28, and 31 from the gp120MN sequence.
Predicted structure of the complement-activating sequence 233-2.51. Figure 4 shows the predicted structure of the complement-activating sequence 233-251, which is located within the constant C2 region of gp120 from the For personal use only. on September 24, 2017. by guest www.bloodjournal.org From the human complement system.' We now provide evidence that distinct sites in the gp120 molecule of HIV-1 activate human complement via the classical pathway in an antibodyindependent manner. Using overlapping peptides obtained from two different HIV-1 isolates, BRU and MN, we were able to confine one strong complement-activating site to the gp120 amino acid sequence spanning the residues 233 to 251 of the conserved C2 region. An additional strong complement-activating site could be identified within the gp120 sequence 321-360 of the MN isolate, which includes the carboxy-terminal flank of the gp120 v3-100~ epitope. Unfortunately, the corresponding sequence was not covered entirely by the BRU peptides. The available BRU-peptides from this region and other v3-loop peptides from the BRU isolate induced only weak complement activation.
Using two different protein structure-prediction programs by Chou and Fasman3' and Gamier et al,36 we found that the gp120 sequence 233-251 contains a p-turn/p-sheet structure. Interestingly, a peptide derived from the previously described complement-activating gp41 sequence 609-623 also is predicted to form, although in the opposite direction, a psheet/p-turn structure, which might be related to the complement-activating capacity of both sequences.
Glycosylation of a protein may be important for complement activation. Recently Haurum et aIz5 pointed out that the so-called "lectin pathway," mediated by the binding of mannan-binding protein (MBP), may represent a means of rgpl2O-induced complement activation. Our present finding that an unglycosylated peptide derived from the gp120 sequence of HIV-1 activates complement via the classical pathway suggests that the amino acid sequence is at least as important as the glycosylation pattern. It should also be considered that the described complement-activating sites 233-251 and 321-360 of gp120 include three and four potential N-glycosylation sites (N-Sm), respectively. Glycosylation may inhibit complement activation especially when carbohydrate moieties are ~ialylated.~' However, the involvement of MBP in complement activation by gp120 instead suggests that in the native molecule, via binding of MBP, the complement-activating capacity of these sequences will be further enhanced.
Although we observed Clq-binding to complement-activating sequences, complement activation did not in all cases correlate directly with the Clq-binding. Furthermore, it is known that Clq-binding may occur without subsequent activation of the macromolecular C l complex. Moreover, besides C lq-triggered activation other mechanisms may be operative to initiate the cascade reaction. We obtained preliminary evidence that rgpl20 and the gp120 sequence 233-251 may mimic Clq and reconstitute Clq-deficient serum in complement activation studies, which is in line with the recently published competition between Clq and gp120 in binding to gp41.38
The gp120 sequences 233-251 and 321-360 were very effective in activating complement. In addition, there were several other sequences, such as 355-383, the CD4-binding region, and the immunodominant v3-100~ region, that appeared to contribute weakly to the complement-activating capacity of gp120. It is currently not known whether sequence 321-360, which belongs to the variable v3-100~ and to the constant C3 region of gp120, and sequence 233-251, which belongs to the constant C2 region of gp120, are exposed. 39 One could postulate that in vivo metabolism would render these two sequences able of exerting their complement-activating properties. Because of two cysteins at positions 233 and 241, the sequence 233-251 is capable of forming a loop.
There is increasing evidence that the direct cytopathic effect of HIV-1 is not the sole reason for the elimination of CD4+ T cells in HIV-infected individuals.4o" We and others have proposed that attachment of HIV-1 glycoprotein gpl20 and anti-gpl20 antibodies to the CD4+ T-cell surface is a key event for the elimination of uninfected CD4+ T ~e l l s .~~,~~.~ Our previous and current results with regard to complement activation by gp120 suggest an additional mechanism for the elimination of uninfected CD4' T cells. C3 may deposit on the surface of CD4+ T cells that have bound free-circulating gp120 molecules. This may lead to the interaction with CR-bearing cells of the monocytic lineage and, thereby, induce phagocytosis. Furthermore, infection of CD4' T cells by HIV-1 may be enhanced after C3b opsonization of the virus and subsequent binding to CRS,'~''' especially in lymph nodes and during early stages of HIV disease before the generation of anti-HIV-1 antibodies. Deposition of complement fragments on the surface of HIV-l -infected cells was shown to mediate their adherence to cells bearing CR1 and CR3.3 This may promote phagocytosis and facilitate virus propagation. Complement-activating HIV-l -infected lymphocytes were shown to have increased sensitivity to cell-mediated natural killing, a phenomenon that can be explained by interaction with CRs that are present on natural killer cell^.'^ The appearance of Ig-gpl20-C3d complexes on CD4' T cells is associated with CD4+ T-cell depletion in HIV-1 -infected patients3' However, our current findings show that the presence of anti-gpl20 antibodies is not a prerequisite for complement activation. Complement proteins can bind to CD4+ T cells even in the absence of antigp120 antibodies if circulating gp120 is attached to the cell surface.
In the present study, we show that specific sites in the gp120 subcomponent of HIV-1 glycoprotein gp160 can activate complement in an antibody-and glycosylation-independent manner. Complement activation by gp120 is in line with our hypothesis that this molecule has Ig-like propertie^.^^.^' The previously reported consumption of complement proteins in AIDWAIDS-related complex patient^'^.^^ that results from a long-lasting, however not host-protecting, activation of the complement system by viral proteins may lead to an additional impairment of the patient's immune system in the defense against opportunistic infections.
